FinTech Dev and Data
Stock Risk Measures for Rocket Pharmaceuticals Inc
A quantitative factor review, as of July 31, 2020.
- Company Info - Description, identity and sector data.
- Share Data - Stock earnings and key dates.
- Market Risk - Beta, size, liquidity and momentum measures.
- Financial Risk - Earnings and dividends.
Updated: August 02, 2020
See how we arrive at an overall risk score of
for RCKT below.
RCKT Risk Report
Our quantitative data points are meant to provide a high-level understanding of
factors in equity risk models for Rocket Pharmaceuticals Inc. Portfolio managers use these
models to forecast risk, optimize portfolios and review performance.
We show how RCKT stock compares to 2,000+ US-based stocks, and to
peers in the Health Technology sector and Biotechnology industry.
Please do not consider this data as investment advice. Data is downloaded from
sources we deem reliable, but errors may occur.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
Sector and Industry
- Sector: Health Technology
- Industry: Biotechnology
- SIC Code: 2836
Shares and Float
- Shares Outstanding: 55,157,000
- Shares Trading: 51,169,976
- Percent Trading: 92.8 %
Earnings and Dividends
- Trailing 12-month earnings: -1.6
- Next earnings date: 2020-08-05
- Dividends in last 12 months: None
- Ex-dividend date: None
Market Risk Measures
Many of the following risk metrics are standardized and transformed into
quantitative factors in institutional-level risk models.
Rankings below represent percentiles from 1 to 100, with 1 being the lowest
rating of risk.
Stocks with higher beta exhibit higher sensitivity to the ups and downs
in the market. (↑↑)
Beta: 1.19 |
Stocks with higher market capitalization often have lower risk. (↑↓)
Market Capitalization: $1,297,844,210 |
Higher average daily dollar volume over the past 30 days implies lower
liquidity risk. (↑↓)
Daily Dollar Volume: $12,560,610 |
Higher price momentum stocks, aka recent winners, equate to lower risk for many
Stock Price Change (1-Year): 91.3% |
Financial Risk Measures
Style risk factors often include measures of profitability and payout levels.
Companies with higher earnings generally provide lower risk. (↑↓)
Earnings Yield (E/P): -6.8% |
Companies with higher dividend yields, if sustaintable, are perceived to
have lower risk. (↑↓)
Dividend Yield (D/P): 0% |
RCKT stock risk
ROCKET PHARMACEUTICALS INC stock beta
RCKT risk report
RCKT risk analysis
ROCKET PHARMACEUTICALS INC credit risk
RCKT liquidity risk
RCKT systematic risk
RCKT specific risk
ROCKET PHARMACEUTICALS INC volatility
RCKT financial ratio